HSPA9 and cancer: This phenomenon has been observed in vitro in multiple cancer cell lines, including NIH/3T3, A-172, U-2 OS, and HeLa, where its interaction with HspA9 prevents nuclear translocation, thereby inhibiting its transcriptional activity and promoting its degradation via the proteasome [103].